4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) announced its quarterly earnings results on Thursday. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02), FiscalAI reports. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The company had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million.

4D Molecular Therapeutics Trading Down 1.9%

Shares of FDMT traded down $0.22 during mid-day trading on Thursday, hitting $11.65. 707,232 shares of the company’s stock were exchanged, compared to its average volume of 788,375. 4D Molecular Therapeutics has a fifty-two week low of $5.97 and a fifty-two week high of $14.00. The business’s 50 day moving average is $10.84 and its two-hundred day moving average is $9.83. The firm has a market capitalization of $609.06 million, a P/E ratio of -4.53 and a beta of 2.73.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Chardan Capital raised 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.75.

Insider Activity

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares of the company’s stock, valued at $9,867,817.95. This represents a 10.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Scott Bizily sold 9,810 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 197,226 shares of company stock worth $2,200,677 in the last 90 days. 7.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. increased its stake in 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after buying an additional 1,090,000 shares during the period. Janus Henderson Group PLC lifted its stake in shares of 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock worth $34,726,000 after acquiring an additional 2,882,508 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of 4D Molecular Therapeutics by 4.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock valued at $32,272,000 after acquiring an additional 174,489 shares in the last quarter. State Street Corp boosted its holdings in shares of 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after acquiring an additional 1,785,106 shares in the last quarter. Finally, Federated Hermes Inc. increased its stake in shares of 4D Molecular Therapeutics by 33.4% during the second quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company’s stock worth $6,186,000 after acquiring an additional 417,157 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.